These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 29487224)

  • 1. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
    Tannir NM; Pal SK; Atkins MB
    Oncologist; 2018 May; 23(5):540-555. PubMed ID: 29487224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Borchiellini D
    Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib for the treatment of kidney cancer.
    Študentová H; Vitásková D; Melichar B
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
    Osanto S; van der Hulle T
    Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.
    Karner C; Kew K; Wakefield V; Masento N; Edwards SJ
    BMJ Open; 2019 Mar; 9(3):e024691. PubMed ID: 30826762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
    Tannir NM; Schwab G; Grünwald V
    Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
    Zahoor H; Rini BI
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
    Markham A
    Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
    Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
    Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
    O'Reilly A; Larkin J
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):251-262. PubMed ID: 28224821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment sequences for advanced renal cell carcinoma: A health economic assessment.
    Deniz B; Ambavane A; Yang S; Altincatal A; Doan J; Rao S; Michaelson MD
    PLoS One; 2019; 14(8):e0215761. PubMed ID: 31465470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
    Al-Salama ZT; Keating GM
    Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
    Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
    Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in treatment of metastatic renal cell carcinoma.
    Gong J; Gerendash B; Dizman N; Khan A; Pal SK
    Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current management of metastatic renal cell carcinoma: evolving new therapies.
    Kumar R; Kapoor A
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):231-237. PubMed ID: 28590313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
    Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
    J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.